



Pharmaceutical Fellowship Program

2026-2028

A message from Zevra Leadership

At Zevra Therapeutics, we recognize that the future of rare-disease innovation depends on developing talented professionals who are eager to grow and contribute.

Our Pharmaceutical Fellowship Program is built with that belief at its core. We offer fellows the opportunity to step into meaningful work from the start, gaining practical experience that directly supports our mission to bring new options to patients with limited treatments.

Throughout the program, fellows will work closely with teams across the organization, engaging in projects that sharpen scientific, strategic, and collaborative skills. We are committed to creating an environment where curiosity is encouraged, ideas are valued, and growth is continuous. Fellows at Zevra are not just observers; they are active contributors whose work helps move critical programs forward.

We look forward to welcoming PharmD and PhD candidates who are motivated by purpose, inspired by innovation, and ready to help shape what's possible for rare-disease communities.



Mary-Jean Fanelli, MD
VP, Medical Affairs
Zevra Therapeutics



ABOUT US

We are a purpose-driven company with a proven record of bringing new therapies to patients.

WHO WE ARE

We are a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. We have a diverse portfolio of products and product candidates, which includes clinical and commercial stage assets. We collaborate with our community to involve key thought leaders, physicians, patients, care partners and advocacy groups in our development strategies.

With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By implementing data-driven development and commercialization strategies, we are overcoming complex drug development challenges to make new therapies available to the rare disease community.

We have therapies approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), urea cycle disorders (UCDs), and a partnered program for attention deficit hyperactivity disorder (ADHD).



VISION STATEMENT

To become a leading rare disease therapeutics company that is driven by patient insights and innovation to make a transformational impact on the people we serve.

OUR PIPELINE

SCIENCE AND PIPELINE

We are dedicated to developing transformational, patient-focused therapies for rare diseases with limited or no treatment options available, or treatment areas with significant unmet needs. Our expertise and science-driven approach has produced a late-stage rare disease clinical pipeline and multiple commercial products.

The below product candidates are under investigation.

PRODUCT CANDIDATE	INDICATION	PHASE 1	PHASE 2	PHASE 3	NDA-MAA SUBMISSION	MILESTONES
NIEMANN-PICK DISEASE TYPE C PROGRAM						
<p>Arimoclomol</p>	Niemann-Pick disease type C (NPC)				<p>Filed Marketing Authorization Application with the European Medicines Agency.</p>	
<p>About Arimoclomol</p> <p>Arimoclomol is under review by the European Medicines Agency (EMA) for the treatment of Niemann-Pick disease type C (NPC). Arimoclomol increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. Arimoclomol has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal Phase 3 trial, arimoclomol halted disease progression compared to placebo in patients taking miglustat over the twelve month duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. Arimoclomol has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC.</p>						
VASCULAR EHLERS-DANLOS SYNDROME PROGRAM						
<p>Celiprolol</p> <p>New chemical entity for the treatment of COL3A1-positive VEDS.</p>	Vascular Ehlers-Danlos Syndrome (VEDS)				<p>Phase 3 trial ongoing</p>	
<p>About Celiprolol</p> <p>Celiprolol is a selective adrenoceptor modulator, or a unique type of beta blocker, believed to decrease mechanical stress on the vascular wall of large arteries and hollow organs. It is currently in Phase 3 development for the treatment of COL3A1-positive VEDS patients to potentially reduce the risk of arterial and other hollow organ clinical events. The Phase 3 DISCOVER trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. FDA. Celiprolol has been granted orphan drug designation and breakthrough therapy designation by the U.S. FDA. Click here to learn more about the DISCOVER trial. Click here for the Celiprolol Fact Sheet.</p>						
RARE SLEEP DISORDERS PROGRAM						
<p>KP1077</p> <p>Prodrug candidate for IH and narcolepsy type I & II</p>	<p>Idiopathic Hypersomnia (IH)</p> <p>Narcolepsy</p>				<p>Phase 3 trial roady</p> <p>Phase 3 trial potential</p>	
<p>About KP1077</p> <p>KP1077 is an investigational product candidate for the treatment of idiopathic hypersomnia (IH) and narcolepsy, respectively. IH is a rare neurological sleep disorder that can exhibit symptoms similar to narcolepsy. Narcolepsy is a chronic neurological disorder that affects the brain's ability to control sleep-wake cycles.</p> <p>KP1077 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH and may be eligible for expedited approval pathways. The U.S. Drug Enforcement Agency (DEA) has classified SDX as a Schedule IV controlled substance based on evidence suggesting SDX has a lower potential for abuse when compared to d-MPH, a Schedule II controlled substance.</p> <p>KP1077 in Idiopathic Hypersomnia</p> <p>Zevra completed a multicenter, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal Phase 2 clinical trial to evaluate the safety and efficacy of KP1077 as a treatment for IH.</p> <p>KP1077 in Narcolepsy</p> <p>A Phase 1 clinical trial under the narcolepsy IND was completed for KP1077 in healthy volunteers to support clinical development of both narcolepsy and IH programs. This trial provided additional information for optimizing the dosing regimen of KP1077.</p> <p>LEARN MORE</p>						

These product candidates are under investigation and their safety and efficacy have not been established. There is no guarantee that these products will receive health authority approval or become commercially available for the uses being investigated.

Fellowship Program Overview

Zevra Therapeutics – Global Medical Affairs Fellowship Two-Year Fellowship | Boston, Massachusetts

The **Zevra Therapeutics Global Medical Affairs Fellowship Program**, offered in partnership with Northeastern University is a two-year postdoctoral program that provides **PharmD** and **PhD graduates** with a unique opportunity to gain comprehensive, hands-on experience within a mission-driven, commercial-stage biopharmaceutical company.

Fellows will strengthen their Medical Affairs expertise while supporting therapies that address unmet needs. The program prepares future rare-disease leaders through exposure to **core Medical Affairs functions** - including **Scientific Communications, Medical Information, Field Medical, and Medical Strategy**.

This broad experience equips fellows with a versatile skill set rooted in scientific rigor, regulatory understanding, and patient-centered impact.

What makes the Zevra Fellowship Program unique?

- Experience a fast-paced, agile biotech environment with direct exposure to high-impact decision making
- Work alongside top scientific and medical leaders with extensive industry experience
- Gain broad experience through a dynamic rotational model spanning Scientific Communications, Medical Information, Field Medical, and Medical Strategy
- Train in Boston, the world's leading hub for biotechnology and rare-disease innovation

“

We are excited to launch our new fellowship program with Northeastern University, reflecting our commitment to developing future Medical Affairs leaders. Our goal is to provide hands-on training across core Medical Affairs functions within a fast-paced, collaborative, and mission-driven environment.

”



Kate Dryga, MBA, MWC
Director, Medical Information
and Scientific Communications
Fellowship Director


Global Medical Affairs Fellowship

Recruiting 1 fellow for 2026-2028

YEAR 1



YEAR 2



Roles & Responsibilities

Gain knowledge of industry standards, regulations, and best practices related to:

- Engaging healthcare professionals and researchers
- Managing both solicited and unsolicited drug information requests
- Developing non-promotional and promotional materials
- Disseminating clinical and real-world evidence
- Overseeing publication processes
- Creating medical and scientific content
- Planning scientific congresses

CORE ROTATIONS

MEDICAL INFORMATION
SCIENTIFIC COMMUNICATIONS
MEDICAL STRATEGY
FIELD MEDICAL/MSL

ADDITIONAL ROTATIONAL OPPORTUNITIES (based on fellow's interest)

PUBLICATIONS
MEDICAL OPERATIONS AND EXCELLENCE
MEDICAL EDUCATION

